Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
8660319 | Heart Rhythm | 2018 | 26 Pages |
Abstract
Ivabradine effectively reduces heart rate and symptoms in IST, but no study was adequately powered to account for the expected placebo effect on symptoms. A multicenter, randomized, placebo-controlled, active, comparative study with a β-blocker is needed for confirmation. This is especially relevant given the ivabradine's potential teratogenic effect, as many IST patients are females of childbearing potential.
Related Topics
Health Sciences
Medicine and Dentistry
Cardiology and Cardiovascular Medicine
Authors
Sunil T. MD, Sunny S. MD, PhD, FHRS, Udho MD, FACC, FAHA,